active substances: magnesium, pyridoxine;
1 tablet contains magnesium citrate anhydrous 618,43 mg (equivalent to 100 mg) and pyridoxine hydrochloride (vitamin B6) 10 mg;
excipients: lactose anhydrous, macrogol 6000, magnesium stearate;
coating: hypromellose, macrogol 6000, titanium dioxide (E 171), talc.
Dosage form. Tablets, film-coated.
Basic physical and chemical properties: white oval tablets, film-coated.
Pharmacotherapeutic group. The b-complex vitamins with minerals.
Code ATX А11Е S.
Magnesium is a cation that is mainly located inside the cells. Magnesium reduces neuronal excitability and neuromuscular transmission, it takes part in many enzymatic processes.
Magnesium is an important component of body tissues: the bones of the skeleton contain half of the total amount of magnesium present in the body.
The concentration of magnesium in serum from 12 to 17 mg/l (1-1,4 mEq/l or 0.5 to 0.7 mmol/l) indicates magnesium deficiency; below 12 mg/l (1 mEq/l or 0.5 mmol/l) – severe magnesium deficiency.
Insufficiency of magnesium may be:
primary, in relation to metabolic pathology (chronic congenital hypomagnesemia);
secondary, in connection with:
inadequate intake of magnesium from food (severe malnutrition, chronic alcohol abuse, parenteral nutrition exclusively),
malabsorption of magnesium in the gastrointestinal tract (chronic diarrhea, fistulas of the gastrointestinal tract, goperations),
excessive loss of magnesium by the kidneys (kanaltsev disorders, severe polyuria, diuretics abuse, chronic pyelonephritis, primary hyperaldosteronism, treatment with cisplatin).
Pyridoxine, kofermentnoy factor that participates in most metabolic processes.
Part of the magnesium salts are passively absorbed in the intestine. The degree of absorption depends on solubility of salts. The absorption of magnesium salts in the digestive tract does not exceed 50%. Magnesium is excreted mainly with urine.
In the body, pyridoxine is subjected to oxidation to piridoxal or amoving to piridoksamin. As a result of further phosphorylation to form phosphate peridocally. This form of pyridoxine is metabolically active.
Symptomatic treatment of magnesium deficiency in the body.
This medicine contains magnesium.
A combination of several of the following symptoms may indicate a deficiency of magnesium in the body:
irritability, irritability, anxiety, transient weakness, slight sleep disturbance,
signs of anxiety which are manifested gastrointestinal spasms or increased heartbeat (no heart disease),
muscle cramps, tingling sensation in the muscles.
The purpose of magnesium can help reduce or eliminate these symptoms.
If the drug is applied, the symptoms do not diminish, continuation of treatment is inappropriate.
Hypersensitivity to any component of the drug. Severe renal insufficiency (creatinine clearance < 30 ml/min). Children up to age 6 years. Phenylketonuria. Hypermagnesemia, hypervitaminosis of vitamin B6, myasthenia gravis. Atrioventricular block, severe hypotension. Concurrent use with levodopa (see section "Interaction with other medicinal products and other forms of interaction"). Diarrhea.
Special security measures
This medicinal product contains lactose. In this regard, it is not recommended to apply it to patients who have galactose intolerance, Lapp lactase deficiency and malabsorption syndrome glucose or galactose (rare hereditary conditions).
Information for diabetics: tablets, film-coated, may contain sucrose as excipients.
Abuse of pyridoxine may lead to the development of sensory neuropathy provided it is taken in high doses (>200 mg/day) over a long period of time (i.e. over several months or years). This effect is usually reversible and disappears after discontinuation of the drug.
For moderate kidney failure, it is necessary to take measures to prevent the occurrence of gipermagniemii.
If after one month of treatment there is no improvement, the drug should be discontinued.
In the case of simultaneous deficiency of calcium, you must first correct a magnesium deficiency and then a calcium deficiency.
Precautions when using
THIS MEDICINAL PRODUCT IS INTENDED FOR USE ONLY ADULTS AND CHILDREN OVER 6 YEARS.
Patients with moderate renal insufficiency should take measures to prevent any risks associated with grermany.
Interaction with other medicinal products and other forms of interaction
Avoid concurrent use with levodopa because the action of levodopa is inhibited when it is not combined with the inhibitors of peripheral DOPA-decarboxylase. The use of pyridoxine in any quantities not shown, if taking levodopa is not accompanied by inhibitors of DOPA-decarboxylase.
Combinations that are not recommended.
Preparations containing phosphate or calcium salt, as they prevent absorption of magnesium from the intestines.
Combinations to be taken into account.
Oral tetracyclines and Magne-B6® Antistress must be taken at intervals of not less than 3 hours, because magnesium suppresses the absorption of tetracyclines.
Magnesium preparations weaken the action of oral anticoagulants and reduce the absorption of iron.
Diuretics increase the excretion of magnesium in the urine.
Application hydralazine, isoniazid, penicillamine and oral contraceptives increases the need for vitamin B6.
Use during pregnancy or breast-feeding.
Pregnancy. Enough data concerning the clinical use of the drug in pregnant women has not revealed fetotoksicheskoe or embryotoxic effect of the drug. Thus, the use of magnesium in pregnancy is possible only, if necessary, after consultation with the doctor.
The lactation period. Each of the active ingredients of the product separately (and magnesium, and vitamin B6) is not contraindicated in this period. Given the limited evidence available today regarding the application of the maximum recommended daily dose of vitamin B6 in the breast-feeding period, it is recommended to assign not more than 20 mg/day of vitamin B6.
The ability to influence the reaction rate when driving motor transport or operating other mechanisms. Not affected.
Method of application and doses
Tablets should be swallowed whole, squeezed 1 Cup of water.
For adults: 3-4 tablets per day, 2 or 3 doses during meals.
For children aged 6 years (body weight approximately 20 kg): 10-30 mg/kg of body weight per day (0,4-1,2 mmol/kg of body weight per day) or 2-4 tablets per day) for 2 or 3 doses during meals. The usual duration of treatment is one month.
Children. The drug is used in children aged 6 years. For use in children under 6 years available in appropriate dosage forms.
Usually oral overdose of magnesium does not cause any toxic reactions in normal renal function. However, magnesium toxicity can develop in the case of kidney failure.
In applying the drug in high doses and over a long period may experience sensory neuropathy, which can manifest in symptoms such as numbness, impaired perception of position, vibration the lower extremities, progression of sensory ataxia (impaired coordination).
Overdose symptoms vary depending on the level of magnesium in the blood serum. In case of overdose may experience a drop in blood pressure, nausea, vomiting, depression of the Central nervous system, slowing of reflexes, abnormal ECG, respiratory failure, coma, cardiac arrest and respiratory paralysis, anuria.
Treatment of overdose: rehydration, forced diuresis. In renal failure required hemodialysis or peritoneal dialysis.
Adverse reactions. Allergic reactions, diarrhea, nausea, vomiting, abdominal pain, skin reactions, including itching and hives.
Shelf life. 2 years.
Storage conditions. Keep out of reach of children. Keep at temperature not exceeding 30 °C.
Packaging. 60 tablets (15х4): 15 tablets in a blister, for 4 blisters in a cardboard box.